Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | GRM7 | Q14831 | 3/20 | 0.38 |
| ▸ | XPO1 | O14980 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288550 | 0.86 | GRM7 (0.41) | S1PR1GRM7XPO1MAPTGSK3A | |
| SCHEMBL6291459 | 0.85 | S1PR1 (0.37) | S1PR1GRM7XPO1MAPTGSK3A | |
| SCHEMBL6288552 | 0.84 | GRM7 (0.38) | S1PR1GRM7XPO1MAPTGSK3A | |
| SCHEMBL6291832 | 0.79 | GRM7 (0.41) | GRM7MAPTNPC1 | |
| SCHEMBL6288587 | 0.78 | GRM7 (0.44) | GRM7MAPTNPC1 | |
| SCHEMBL6288364 | 0.78 | GRM7 (0.39) | GRM7MAPT | |
| SCHEMBL6291398 | 0.76 | GRM7 (0.40) | GRM7MAPT | |
| SCHEMBL6288411 | 0.76 | TUBB4A (0.36) | XPO1PDE10ADRD1DRD5HRH4 | |
| SCHEMBL6291872 | 0.72 | PDE5A (0.42) | PDE10ADRD1DRD5CASR | |
| SCHEMBL6288398 | 0.72 | ALDH1A1 (0.42) | GRM7PDE10AMEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936609-B2 | Imidazotriazines for use as phosphodiesterase inhibitors | BAYER HEALTHCARE AG (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040249148-A1 | Imidazotriazines for use as phosphodiesterase inhibitors | BAYER HEALTHCARE AG (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1404677-A1 | IMIDAZOTRIAZINES FOR USE AS PHOSPHODIESTERASE INHIBITORS | Bayer HealthCare AG (DE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003000693-A1 | IMIDAZOTRIAZINES FOR USE AS PHOSPHODIESTERASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249148-A1 | Imidazotriazines for use as phosphodiesterase inhibitors | PDE3A, PDE2A, PDE4A | S1PR1 2809/4885GRM7 2512/4885XPO1 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.